Fifth Third Bancorp Has $3.89 Million Stock Position in Kenvue Inc. $KVUE

Fifth Third Bancorp increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 17.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 225,399 shares of the company’s stock after buying an additional 34,099 shares during the period. Fifth Third Bancorp’s holdings in Kenvue were worth $3,888,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Physician Wealth Advisors Inc. lifted its position in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares in the last quarter. Cornerstone Planning Group LLC lifted its position in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares in the last quarter. NBT Bank N A NY lifted its position in Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the period. Salomon & Ludwin LLC acquired a new position in Kenvue during the 3rd quarter valued at about $25,000. Finally, Golden State Wealth Management LLC lifted its position in Kenvue by 150.1% during the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after purchasing an additional 1,190 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $17.44 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The stock has a market cap of $33.48 billion, a PE ratio of 22.65, a price-to-earnings-growth ratio of 3.96 and a beta of 0.55. The stock has a 50-day moving average of $17.72 and a 200-day moving average of $17.19. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.Kenvue’s revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 EPS. As a group, sell-side analysts expect that Kenvue Inc. will post 1.1 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be paid a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is 107.79%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research reports. Jefferies Financial Group downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Argus upgraded shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research report on Wednesday, April 8th. Citigroup cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Finally, Canaccord Genuity Group upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.